-

QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today has released preliminary Q2 2021 results and an updated outlook for full-year 2021.

A conference call is planned for Tuesday, July 13, 2021, at 15:00 CET / 9:00 EDT, hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

Conference call and webcast details

Interested parties may listen to the call by dialing:

+1 929 477 0402 (U.S.), +44 (0)330 336 9125 (UK), +49 (0) 69 2222 25574 (Germany).

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
Conference ID:
7999995

The webcast will be accessible at:
https://globalmeet.webcasts.com/starthere.jsp?ei=1479747&tp_key=f5369b458c

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1479747&tp_key=f5369b458c

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2021, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Contacts

John Gilardi
Vice President Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

QIAGEN N.V.

FWB:QIA
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)

Release Summary
QIAGEN N.V. conference call on July 13 to discuss preliminary Q2 2021 results
Release Versions

Contacts

John Gilardi
Vice President Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

More News From QIAGEN N.V.

QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board at an Extraordinary General Meeting of Shareholders. Jon Pratt joined QIAGEN as Chief Executive Officer on September 1, 2026. Following today’s shareholder approval, he joins Roland Sackers, Chief Financial Officer, on QIAGEN’s Managing Board. Shar...

QIAGEN Reports Full Q3 2026 Results

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced full results for the third quarter of 2026, with net sales and adjusted diluted earnings per share (EPS) ahead of the outlook. In line with preliminary results, Q3 2026 sales rose 3% to $548 million compared with Q3 2025, also increasing 3% at constant exchange rates (CER) and exceeding the outlook for about 1-2% CER growth. Consumables and related revenues rose 3% CER...

QIAGEN reports preliminary Q3 2026 results

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates (CER). Adjusted diluted earnings per share (EPS) were $0.65, also $0.65 CER. QIAGEN plans to report full Q3 2026 results on Wednesday, November 4, 2026, at approximately 22:05 Frankfurt time / 16:05 New York time. Given the announced transaction wit...
Back to Newsroom